Clinical Study of Salmeterol Xinafoate (SN408) Dry Powder. Examination in Patients with Bronchical Asthma.
|
Accession number;02A0595852
|
| Title;Clinical Study of Salmeterol Xinafoate (SN408) Dry Powder. Examination in Patients with Bronchical Asthma. |
| Author;
MAKINO SOHEI
(Dokkyo Univ. Sch. of Med.)
|
Journal Title;Journal of Clinical Therapeutics & Medicines
|
Journal Code:Y0906A
|
ISSN:0910-8211
|
|
VOL.18;NO.6;PAGE.791-805(2002)
|
| Figure&Table&Reference;FIG.11, TBL.12, REF.16 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Following results were obtained by administering 50.MU.g b.i.d. (in morning and before bed-time) of salmeterol xinafoate dry powder to patients with bronchial asthma for 4 consecutive weeks. 1) Significant improvement or tendency to improve compared to pre-dosing was observed in symptom scores such as attack scores, treatment scores, asthma scores and PEF at rising and in night measured by peak flow meter. 2) In overall improvement where good efficacy was seen, 22.0%, 61.0% and 90.2% of patients were assessed as "Markedly improved", "Moderately improved" or better and "Mildly improved" or better, respectively. 3) As to clinical usefulness, 21.4% was evaluated as "Very useful", 59.5% as "Useful" or better, and 90.5% as "Slightly useful" or better. Here also, sufficient results were obtained. 4) As for adverse events, one case of thirstiness and another case of cough were observed out of 45 cases. For these cases with advers events, administration could be continued. No other problem in safety regarded to be associated with salmeterol had appeared, and "Relatively safe" or better was achieved by 100% of the cases. In conclusion, excellent efficacy and safety of this drug were established following the 4-week dosing, suggesting that it is a very useful drug in treatment of bronchial asthma. (author abst.) |
|
|
|
Related Articles;
|
|
